However, the recent ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II) trial demonstrated that CSL112, an apoA-I infusion therapy that enhances cellular cholesterol efflux, does not reduce ASCVD events when administered soon after an acute myocardial infarction (MI) [30]. This evidence concerns the gene APOA1 and acute myocardial infarction.